Figure 3. Hebp1 and Glo1 exhibit increased expression in brains of patients with rapidly-progressing forms of AD.

(A) Immunoblot analysis of Hebp1 and Glo1 expression in slow-progressing (spAD) and rapidly-progressing (rpAD) AD cases and age-matched controls. Samples from nine control, eight slow-progressing AD and eight rapidly-progressing AD patients were used in this study. Detailed information on the patients is presented in Table 2. Quantification of (B) Hebp1 and (C) Glo1 levels in human samples. Error bars in graphs represent mean ± SD. Statistical significance in the datasets was assessed by one-way ANOVA followed by Bonferroni’s multiple comparisons test for individual pairs of samples (α = 0.05): *p<0.025, **p<0.01, and ***p<0.0001.

Figure 3—figure supplement 1. HEBP1 expression in publicly available transcriptome databases of Alzheimer’s disease.

In silico analysis of HEBP1 mRNA expression in AD patients and matched controls based on publicly available data from Harvard Brain Tissue Resource Center (HBTRC) deposited on GeneNetwork (www.genenetwork.org) (see Materials and methods for details). HEBP1 expression in prefrontal cortex (A), primary visual cortex (B) and cerebellum (C) is significantly elevated in AD patients. Violin plots represent all analyzed values. Dashed and dotted red lines indicate median and the 25^th or 75^th percentile, respectively. Number of patients per group is indicated at the x-axes on the graphs. Mann-Whitney test was used to assess statistical significance.